NRXS vs. TELA, SPAI, LUNG, QTI, PYPD, EDAP, SRTS, MDAI, DXR, and ICCM
Should you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include TELA Bio (TELA), Safe Pro Group (SPAI), Pulmonx (LUNG), QT Imaging (QTI), PolyPid (PYPD), EDAP TMS (EDAP), Sensus Healthcare (SRTS), Spectral AI (MDAI), Daxor (DXR), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry.
NeurAxis vs. Its Competitors
TELA Bio (NASDAQ:TELA) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
TELA Bio has a net margin of -54.12% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat TELA Bio's return on equity.
TELA Bio presently has a consensus target price of $4.50, suggesting a potential upside of 150.00%. NeurAxis has a consensus target price of $7.00, suggesting a potential upside of 185.71%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts clearly believe NeurAxis is more favorable than TELA Bio.
94.3% of TELA Bio shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 4.7% of TELA Bio shares are owned by insiders. Comparatively, 26.4% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
TELA Bio has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500.
NeurAxis has lower revenue, but higher earnings than TELA Bio. NeurAxis is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, TELA Bio had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for TELA Bio and 1 mentions for NeurAxis. TELA Bio's average media sentiment score of 1.42 beat NeurAxis' score of -0.01 indicating that TELA Bio is being referred to more favorably in the media.
Summary
NeurAxis beats TELA Bio on 9 of the 15 factors compared between the two stocks.
Get NeurAxis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeurAxis Competitors List
Related Companies and Tools
This page (NASDAQ:NRXS) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access